Merck KGaA (FRA:MRK) has been assigned a €70.00 ($81.40) target price by analysts at Barclays in a research note issued to investors on Friday. The firm presently has a “sell” rating on the healthcare company’s stock. Barclays’ price target would suggest a potential downside of 22.19% from the stock’s previous close.
MRK has been the subject of a number of other reports. Sanford C. Bernstein set a €105.00 ($122.09) price objective on Merck KGaA and gave the stock a “buy” rating in a research note on Tuesday, July 3rd. Societe Generale set a €92.00 ($106.98) price objective on Merck KGaA and gave the stock a “neutral” rating in a research note on Friday. UBS Group set a €115.00 ($133.72) price objective on Merck KGaA and gave the stock a “buy” rating in a research note on Tuesday, June 26th. JPMorgan Chase & Co. set a €90.00 ($104.65) price target on Merck KGaA and gave the stock a “neutral” rating in a research note on Wednesday, July 25th. Finally, Citigroup set a €115.00 ($133.72) price target on Merck KGaA and gave the stock a “buy” rating in a research note on Wednesday, June 13th. One research analyst has rated the stock with a sell rating, twelve have given a hold rating and ten have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of €99.59 ($115.80).
Shares of Merck KGaA opened at €89.96 ($104.60) on Friday, according to Marketbeat Ratings. Merck KGaA has a 12 month low of €76.60 ($89.07) and a 12 month high of €115.00 ($133.72).
MERCK Kommanditgesellschaft auf Aktien, a science and technology company, operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Further Reading: Book Value Per Share in Stock Trading
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.